Clinical Trials · NCT01551602

Clinical Study of AK159 in Healthy Postmenopausal Women

CompletedPhase 1Teriparatide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Asahi Kasei Therapeutics Corporation
Enrollment
132
Start date
Mar 2012
Locations
3 sites, Japan
Primary endpoint
Area under the plasma concentration versus time curve (AUC) of teriparatide
View Teriparatide compound reference